{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T19:50:37Z","timestamp":1767901837394,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00262-020-02815-1","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T15:27:47Z","timestamp":1611329267000},"page":"2385-2388","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pembrolizumab-induced immune-mediated fatal colitis with concurrent giardia infection"],"prefix":"10.1007","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8828-122X","authenticated-orcid":false,"given":"Gurhan","family":"Sisman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6258-2443","authenticated-orcid":false,"given":"Erol","family":"Barbur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0706-7844","authenticated-orcid":false,"given":"Didem","family":"Saka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7470-8835","authenticated-orcid":false,"given":"Sibel","family":"Erdamar Cetin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"key":"2815_CR1","unstructured":"Nobel Prize Organisation (2018) The Nobel Prize in Physiology or Medicine 2018. https:\/\/www.nobelprize.org\/prizes\/medicine\/2018\/press-release. Accessed 18 November 2020"},{"key":"2815_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40425-018-0346-6","volume":"6","author":"Y Wang","year":"2018","unstructured":"Wang Y, Abu-Sbeih H, Mao E et al (2018) Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer 6:37. https:\/\/doi.org\/10.1186\/s40425-018-0346-6","journal-title":"J Immunother Cancer"},{"key":"2815_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.12998\/wjcc.v7.i4.405","volume":"7","author":"A Som","year":"2019","unstructured":"Som A, Mandaliya R, Alsaadi D, Farshidpour M, Charabaty A, Malhotra N, Mattar MC (2019) Immune checkpoint inhibitor-induced colitis: a comprehensive review. World J Clin Cases 7:405\u2013418","journal-title":"World J Clin Cases"},{"key":"2815_CR4","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/diagnostics10030146","volume":"10","author":"F Borella","year":"2020","unstructured":"Borella F, Ghisoni E, Giannone G, Cosma S, Benedetto C, Valabrega G, Katsaros D (2020) Immune checkpoint inhibitors in epithelial ovarian cancer: an overview on efficacy and future perspectives. Diagnostics 10:146. https:\/\/doi.org\/10.3390\/diagnostics10030146","journal-title":"Diagnostics"},{"key":"2815_CR5","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721\u20131728","journal-title":"JAMA Oncol"},{"key":"2815_CR6","unstructured":"Food and Drug Administration (2017) FDA approves first cancer treatment for any solid tumor with a specific genetic feature. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-cancer-treatment-any-solid-tumor-specific-genetic-feature. Accessed 18 November 2020"},{"key":"2815_CR7","doi-asserted-by":"publisher","first-page":"6109","DOI":"10.2147\/OTT.S205950","volume":"13","author":"I Palaia","year":"2020","unstructured":"Palaia I, Tomao F, Sassu CM, Musacchio L, Benedetti Panici P (2020) Immunotherapy for ovarian cancer: recent advances and combination therapeutic approaches. Onco Targets Ther 13:6109\u20136129","journal-title":"Onco Targets Ther"},{"key":"2815_CR8","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/annonc\/mdw141","volume":"27","author":"J Naidoo","year":"2016","unstructured":"Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD (2016) Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 27:1362. https:\/\/doi.org\/10.1093\/annonc\/mdw141","journal-title":"Ann Oncol"},{"key":"2815_CR9","doi-asserted-by":"publisher","first-page":"272","DOI":"10.21037\/atm.2016.07.10","volume":"4","author":"H Linardou","year":"2016","unstructured":"Linardou H, Gogas H (2016) Toxicity management of immunotherapy for patients with metastatic melanoma. Ann Transl Med 4:272","journal-title":"Ann Transl Med"},{"key":"2815_CR10","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/apt.13281","volume":"42","author":"A Gupta","year":"2015","unstructured":"Gupta A, De Felice KM, Loftus EV Jr, Khanna S (2015) Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 42:406\u2013417. https:\/\/doi.org\/10.1111\/apt.13281","journal-title":"Aliment Pharmacol Ther"},{"key":"2815_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2478\/pjs-2014-0017","volume":"86","author":"P Dilling","year":"2014","unstructured":"Dilling P, Walczak J, Pikiel P, Kruszewski WJ (2014) Multiple colon perforation as a fatal complication during treatment of metastatic melanoma with ipilimumab\u2014case report. Pol Przegl Chir 86:94\u201396. https:\/\/doi.org\/10.2478\/pjs-2014-0017","journal-title":"Pol Przegl Chir"},{"key":"2815_CR12","doi-asserted-by":"publisher","first-page":"rju010","DOI":"10.1093\/jscr\/rju010","volume":"3","author":"L Burdine","year":"2014","unstructured":"Burdine L, Lai K (2014) Laryea JA (2014) Ipilimumab-induced colonic perforation. J Surg Case Rep 3:rju010. https:\/\/doi.org\/10.1093\/jscr\/rju010","journal-title":"J Surg Case Rep"},{"key":"2815_CR13","doi-asserted-by":"publisher","first-page":"e1182","DOI":"10.7759\/cureus.1182","volume":"9","author":"R Shah","year":"2017","unstructured":"Shah R, Witt D, Asif T, Mir FF (2017) Ipilimumab as a Cause of Severe Pan-colitis and colonic perforation. Cureus 9:e1182. https:\/\/doi.org\/10.7759\/cureus.1182","journal-title":"Cureus"},{"key":"2815_CR14","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1200\/jco.2005.04.5716","volume":"15","author":"KE Beck","year":"2006","unstructured":"Beck KE, Blansfield JA, Tran KQ et al (2006) Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 15:2283\u20132289. https:\/\/doi.org\/10.1200\/jco.2005.04.5716","journal-title":"J Clin Oncol"},{"key":"2815_CR15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/ecco-jcc\/jjv227","volume":"10","author":"L Marthey","year":"2016","unstructured":"Marthey L, Mateus C, Mussini C et al (2016) Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis 10:395\u2013401. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv227","journal-title":"J Crohns Colitis"},{"key":"2815_CR16","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1007\/s10620-008-0641-z","volume":"54","author":"RL Johnston","year":"2009","unstructured":"Johnston RL, Lutzky J, Chodhry A, Barkin JS (2009) Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci 54:2538\u20132540. https:\/\/doi.org\/10.1007\/s10620-008-0641-z","journal-title":"Dig Dis Sci"},{"key":"2815_CR17","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00262-017-1962-6","volume":"66","author":"V Bergqvist","year":"2017","unstructured":"Bergqvist V, Hertervig E, Gedeon P et al (2017) Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother 66:581\u2013592. https:\/\/doi.org\/10.1007\/s00262-017-1962-6","journal-title":"Cancer Immunol Immunother"},{"key":"2815_CR18","doi-asserted-by":"publisher","first-page":"bcr2016216641","DOI":"10.1136\/bcr-2016-216641","volume":"2016","author":"AH Hsieh","year":"2016","unstructured":"Hsieh AH, Ferman M, Brown MP, Andrews JM (2016) Vedolizumab: a novel treatment for ipilimumab-induced colitis. BMJ Case Rep 2016:bcr2016216641. https:\/\/doi.org\/10.1136\/bcr-2016-216641","journal-title":"BMJ Case Rep"},{"key":"2815_CR19","doi-asserted-by":"publisher","first-page":"914","DOI":"10.3390\/toxins6030914","volume":"6","author":"L Gelao","year":"2014","unstructured":"Gelao L, Criscitiello C, Esposito A, Goldhirsch A, Curigliano G (2014) Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an \u201cinnocent bystander.\u201d Toxins (Basel) 6:914\u2013933. https:\/\/doi.org\/10.3390\/toxins6030914","journal-title":"Toxins (Basel)"},{"key":"2815_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16:563\u2013580. https:\/\/doi.org\/10.1038\/s41571-019-0218-0","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02815-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02815-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02815-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T13:05:24Z","timestamp":1626699924000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02815-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["2815"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02815-1","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,22]]},"assertion":[{"value":"15 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The views expressed in the submitted article are the authors\u2019 and not an official position\u2019s of the institution or funder\u2019s.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimers"}}]}}